Roy Freeman - Rxsight Senior Relations

Rxsight Management Efficiency

The company has return on total asset (ROA) of (0.0992) % which means that it has lost $0.0992 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1399) %, meaning that it created substantial loss on money invested by shareholders. Rxsight's management efficiency ratios could be used to measure how well Rxsight manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.25 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. Change To Liabilities is likely to gain to about 6.6 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 15.2 M in 2024.

Similar Executives

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses used in cataract surgery in the United States and internationally. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. Rxsight operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 221 people. Rxsight (RXST) is traded on NASDAQ Exchange in USA. It is located in 100 Columbia, Aliso Viejo, CA, United States, 92656 and employs 374 people. Rxsight is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Rxsight Leadership Team

Rxsight Stock Performance Indicators

Additional Tools for Rxsight Stock Analysis